Postpartum Hemorrhage (PPH) is defined as the loss of more than 500 ml or 1000 ml of blood within the first 24 hours following childbirth. It is generally caused by four major conditions- tone (uterine atony), trauma, tissue (retained placenta), Thrombin (coagulopathy). The treatment devices have been available in the market for more than two decades. Women are at the highest risk of severe complications or maternal death during the first 24 hours postpartum and the first week after childbirth. Uterine balloon tamponades are recommended in case of refractory bleeding or if uterotonics are inaccessible, while non-pneumatic anti-shock garments and external aortic compression are primarily recommended as temporizing measures until the patient has been transferred to an advanced healthcare setting.
The global postpartum hemorrhage treatment devices market report provides market size (Revenue US$ Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global postpartum hemorrhage treatment devices market segmentation is based on product type (non-pneumatic anti-shock garment, Uniject prefilled injection system, uterine balloon tamponade, Foley catheters, condom catheters, etc.).
The global postpartum hemorrhage treatment devices market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global postpartum hemorrhage treatment devices market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global postpartum hemorrhage treatment devices market and included in this report are 3rd Stone Design, Inc., Bactiguard AB, Cook Medical, Inc., C. R. Bard, Inc., Program for Appropriate Technology in Health (PATH), Utah Medical Products, Inc., Teleflex Incorporated, and ZOEX NIASG.